Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 10/20 | 0.38 |
| ▸ | NOS1 | P29475 | 7/20 | 0.38 |
| ▸ | NOS3 | P29474 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16659160 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3CYP3A4TSHR | |
| SCHEMBL14227023 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3CYP3A4TSHR | |
| SCHEMBL13287266 | 1.00 | NOS2 (0.38) | NOS2NOS1NOS3CYP3A4TSHR | |
| SCHEMBL15281109 | 0.91 | NOS2 (0.34) | NOS2NOS1NOS3CYP3A4TSHR | |
| SCHEMBL12438535 | 0.91 | NOS2 (0.50) | NOS2NOS1NOS3CYP3A4TSHR | |
| SCHEMBL15853671 | 0.91 | NOS2 (0.38) | NOS2NOS1NOS3CYP3A4TSHR | |
| SCHEMBL12262870 | 0.91 | NOS2 (0.50) | NOS2NOS1NOS3CYP3A4TSHR | |
| SCHEMBL23676980 | 0.89 | NOS2 (0.33) | NOS2NOS1NOS3 | |
| SCHEMBL18314370 | 0.89 | NOS2 (0.33) | NOS2NOS1NOS3CYP3A4TSHR | |
| SCHEMBL13007992 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759748-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| US-9428453-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2015-04-09 | — | — | US | disclosed |
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2015-04-09 | — | — | US | disclosed |
| US-8916609-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916609-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | NEW YORK UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140187546-A1 | Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-07-03 | — | — | US | disclosed |
| US-20120316236-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-12-13 | — | — | US | disclosed |
| US-20120316236-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-12-13 | — | — | US | disclosed |
| WO-2009017620-A1 | CHEMOKINE ANALOGS | IPSEN PHARMA S.A.S. (FR) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008156677-A2 | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA S.A.S. (FR) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099806-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | ATP6V1B1, GLS, REN | NOS2 1793/4885NOS1 1122/4885NOS3 1995/4885 |
| US-20140187546-A1 | Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria | CTH, CBS, SLC6A12 | NOS2 1102/4885NOS1 949/4885NOS3 827/4885 |
| US-10759748-B2 | Compounds as L-cystine crystallization inhibitors and uses thereof | ATP6V1B1, GLS, REN | NOS2 1793/4885NOS1 1122/4885NOS3 1995/4885 |
| US-20120316236-A1 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF | ATP6V1B1, GLS, REN | NOS2 1793/4885NOS1 1122/4885NOS3 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.